No insider purchase over the last 90 days. The latest, by 김주열, was filed 25 Jun 2026.
ENCell Co., Ltd.: what insiders have been doing
Every trade that managers of ENCell Co., Ltd. disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. In the past year (1 November 2025 to 1 November 2026), 18 filings came from 9 insiders.
The record shows 12 purchases on the open market worth €42k, made by 8 insiders, against 4 sales worth €2.4M by 3 insiders. The totals exclude 11 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €1.3M, sold by Nh투자증권 and made public on 10 March 2026 (3.8% of market cap). On the buying side, the filings list 6 board members and 1 senior executive among the declarants.
With 18 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. Our records for ENCell Co., Ltd. go back to 2024, with 29 purchases and 7 sales on the open market in total.
Within a 30-day window, 2 purchases overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The clock since the last published purchase (25 June 2026) now reads 137 days. Typically, a trade is published a median of 7 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySale+7 other insiders
Since the insiders bought
- -70.8%Entry ₩16,020 · Close 30 Oct 2026 ₩4,675
- -70.8%Entry ₩16,020 · Close 30 Oct 2026 ₩4,675
- -72.0%Entry ₩16,700 · Close 30 Oct 2026 ₩4,675
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- 2,500 sharesShareKRXDART:20260625000186Canonical exit: 23 Sept 2026 (T+90)
- 3,350 sharesShareKRXDART:20260624000089Canonical exit: 22 Sept 2026 (T+90)
- 500 sharesShareKRXDART:20260624000106Canonical exit: 22 Sept 2026 (T+90)
- 564 sharesShareKRXDART:20260624000111Canonical exit: 22 Sept 2026 (T+90)
- 10,000 sharesShareKRXDART:20260520000056
- 117,400 shares2.60% mcap100.0% of flowKRXDART:20260415000437
- 10,000 shares0.25% mcap100.0% of flowKRXDART:20260402003134
- 20,000 shares@ ₩12,969.000.38% mcap100.0% of flowShareKRXDART:20260402002967
- 8,000 shares@ ₩3,500.000.047% mcap100.0% of flowShareKRXDART:20260311004267Canonical exit: 2 Jun 2026 (T+90)
- 12,500 shares@ ₩3,500.000.075% mcap100.0% of flowShareKRXDART:20260311004117Canonical exit: 3 Jun 2026 (T+90)
- 0KRXDART:20260311004337
- 140,685 shares3.79% mcap100.0% of flowKRXDART:20260310002747
- 2,500 sharesShareKRXDART:20260212000894Canonical exit: 13 May 2026 (T+90)
- 5,250 sharesShareKRXDART:20260114000078Canonical exit: 14 Apr 2026 (T+90)
- 7,500 sharesShareKRXDART:20260114000072Canonical exit: 14 Apr 2026 (T+90)
- 956 sharesShareKRXDART:20251215000249Canonical exit: 15 Mar 2026 (T+90)
- 922,953 sharesKRXDART:20251215000447Canonical exit: 12 Mar 2026 (T+90)
- 427 sharesShareKRXDART:20251104000182Canonical exit: 2 Feb 2026 (T+90)
- 659 sharesShareKRXDART:20250930000140Canonical exit: 29 Dec 2025 (T+90)
- 8,500 sharesShareKRXDART:20250411003283Canonical exit: 10 Jul 2025 (T+90)
- 20,000 sharesShareKRXDART:20250411003258Canonical exit: 10 Jul 2025 (T+90)
- 29,175 sharesShareKRXDART:20250411003244Canonical exit: 10 Jul 2025 (T+90)
- 8,900 sharesShareKRXDART:20250411003215Canonical exit: 10 Jul 2025 (T+90)
25 of 40 declarations
About ENCell Co., Ltd.
이엔셀 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative healthcare solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
